Desmopressin Tablet
Desmopressin is a compounded formulation containing Desmopressin, prepared by Mixlab for veterinary use. Available by prescription.
The uses and pharmacology described below reflect the FDA-approved labeling for this active ingredient; your veterinarian determines whether and how they apply to your animal's treatment plan.
Veterinarians most commonly consider desmopressin acetate in an AQ vehicle for the management of central diabetes insipidus. This clinical condition occurs when the posterior pituitary gland does not release adequate amounts of ADH, leading to an inability of the kidneys to concentrate urine. The choice of an aqueous vehicle is frequently discussed when a veterinarian seeks to utilize mucosal administration routes, such as intranasal or ophthalmic (in the eye) application, to achieve systemic absorption of the active ingredient. By utilizing these pathways, veterinarians can manage the physiological challenges of patients that may not tolerate oral formulations or those requiring a specific concentrated volume.
At a pharmacological level, desmopressin acts as a selective agonist for V2 receptors located in the renal collecting ducts. This mechanism manages the reabsorption of water back into the body by increasing the permeability of these ducts. Consequently, this provides a method for managing the high volume of dilute urine (polyuria) and the compensatory excessive thirst (polydipsia) observed in affected pets. Unlike natural vasopressin, desmopressin is characterized by a high degree of V2 selectivity and minimal V1 activity, which means it has a limited influence on vascular smooth muscle and blood pressure. Your veterinarian will determine whether this compounded aqueous formulation is appropriate for your pet based on diagnostic results, such as urine specific gravity tests or water deprivation trials.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring. Compounded drugs are not approved by the FDA for safety or effectiveness.
Commonly observed effects following the administration of desmopressin in an AQ vehicle include localized changes at the application site, such as mild eye redness, squinting or temporary nasal discharge. Because the medication acts by promoting the retention of water, your veterinarian will monitor for observational signs of fluid overload or "water intoxication." These signs may include behavioral shifts, localized swelling (edema), vomiting or unusual lethargy. Owners should monitor their pet for any dramatic changes in energy or breathing and contact their veterinarian promptly with any concerns regarding the patient's response to the medication.
This medication is typically used with extra caution or avoided in patients with known cardiovascular disease, congestive heart failure or severe renal impairment, as the retention of extra fluid can influence the clinical status of these conditions. It is also carefully evaluated in pets with a history of thromboembolic events or those presented with low blood sodium (hyponatremia). Significant interactions can occur if desmopressin is administered concurrently with other medications that influence fluid balance, such as specific diuretics or certain behavioral prescriptions. Your veterinarian is the right person to provide guidance on the necessary frequency of use and the proper monitoring schedule to ensure the management approach remains suitable for your pet's metabolic health.
Yes. Desmopressin in AQ vehicle is a prescription medication and can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab ensures all prescription requirements are met before any compounded medication is prepared or shipped to your home.
Yes. Mixlab specializes in compounding desmopressin into a sterile aqueous vehicle to suit the specific needs of dogs and cats, particularly when commercial formats do not meet the required concentration or volume. The decision to use a compounded formulation rests with the prescribing veterinarian based on your pet's individual diagnostic profile.
Veterinarians often discuss using ophthalmic application for desmopressin because the mucous membranes of the eye allow for the absorption of the medication into the bloodstream. This provides a method for delivering the medication to the kidneys without the need for oral administration or frequent injections.
The most important observational signs include a sudden decrease in energy, swelling of the limbs or changes in breathing patterns. If you notice any unusual lethargy or a dramatic shift in your pet's activity, you should contact your veterinarian immediately for a clinical review of the management plan.
Veterinarians and pharmacists typically recommend keeping this aqueous formulation refrigerated to support the stability of the active ingredient. Your veterinarian will provide specific guidance on the proper handling and storage of your pet's medication to ensure it remains suitable for use throughout the course of management.
